Biopharmaceutical firm TG Therapeutics has obtained a license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to aid the development of a novel immunotherapy. In return, MaxCyte will receive annual licensing fees and program-related revenue. TG Therapeutics, focused on B-cell disease treatments, will launch a Phase I trial for a multiple sclerosis treatment developed with the licensed gene-editing technology.
Lazarus Group hiding malware in GitHub and open-source packages
North Korean hacking group, Lazarus Group, is using malware to steal cryptocurrency, according to SecurityScorecard’s STRIKE Team. The malware, named Marstech1, is planted in “undetectable”
